Michal Sarfaty
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers 10
- HER2/EGFR in Cancer Research 5
- Hepatology top 10%
-
- Renal cell carcinoma treatment 9
- Radiation top 10%
-
- Bladder and Urothelial Cancer Treatments 16
- Urinary and Genital Oncology Studies 6
- Esophageal Cancer Research and Treatment 4
-
- Economic and Financial Impacts of Cancer 7
-
- Frailty in Older Adults 3
- Co-authors
- Assaf MooreDaniel A. GoldsteinNoa GordonVictoria NeimanEli RosenbaumMoshe LeshnoSalomon M. StemmerJonathan E. Rosenberg
- Cited by
- OncologyCancer ResearchHepatology
- Partner nations
- IsraelUnited StatesCanada
In The Last Decade
Michal Sarfaty
44 papers receiving 536 citations
Peers
Comparison fields: 5 of 57
- Oncology 290
- Cancer Research 116
- Hepatology 61
- Pulmonary and Respiratory Medicine 182
- Radiation 37
Countries citing papers authored by Michal Sarfaty
This map shows the geographic impact of Michal Sarfaty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michal Sarfaty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michal Sarfaty more than expected).
Fields of papers citing papers by Michal Sarfaty
This network shows the impact of papers produced by Michal Sarfaty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michal Sarfaty. The network helps show where Michal Sarfaty may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Michal Sarfaty, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2024 | 2 | |
| 3 | 2023 | 0 | |
| 4 | 2023 | 3 | |
| 5 | 2021 | 1 | |
| 6 | 2021 | 2 | |
| 7 | 2021 | 101 | |
| 8 | 2020 | 5 | |
| 9 | 2020 | 4 | |
| 10 | 2019 | 16 | |
| 11 | 2019 | 27 | |
| 12 | 2018 | 49 | |
| 13 | 2017 | 55 | |
| 14 | 2017 | 58 | |
| 15 | 2017 | 2 | |
| 16 | 2017 | 14 | |
| 17 | 2017 | 1 | |
| 18 | 2016 | 4 | |
| 19 | 2016 | 4 | |
| 20 | 2013 | 25 |
About Michal Sarfaty
Michal Sarfaty is a scholar working on Oncology, Geriatrics and Gerontology and Pulmonary and Respiratory Medicine, having authored 46 papers that have together received 539 indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (16 papers), Cancer Immunotherapy and Biomarkers (10 papers), Renal cell carcinoma treatment (9 papers), Economic and Financial Impacts of Cancer (7 papers), Urinary and Genital Oncology Studies (6 papers), HER2/EGFR in Cancer Research (5 papers), Esophageal Cancer Research and Treatment (4 papers) and Frailty in Older Adults (3 papers). The work is most often cited by research in Oncology (290 citations), Cancer Research (116 citations) and Hepatology (61 citations). Michal Sarfaty has collaborated with scholars based in Israel, United States and Canada. Frequent co-authors include Assaf Moore, Daniel A. Goldstein, Noa Gordon, Victoria Neiman, Eli Rosenbaum, Moshe Leshno, Salomon M. Stemmer, Jonathan E. Rosenberg, Hadar Goldvaser and Rinat Yerushalmi. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.